Trial Profile
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced or Refractory Solid Tumors or Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Erdafitinib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Cholangiocarcinoma; Gastric cancer; Glioblastoma; Head and neck cancer; Lung cancer; Lymphoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; First in man
- Sponsors Janssen Research & Development
- 10 Oct 2019 Results of a cross-study analysis of total 7 studies(NCT01703481,NCT02218073,NCT02231489,EuDRACT-2015-001583-19,NCT02692677,NCT03066687and NCT03135106) published in the Journal of Clinical Pharmacology
- 14 May 2019 Results published in the Clinical Cancer Research
- 20 Dec 2017 Status changed from active, no longer recruiting to completed.